Literature DB >> 18391006

Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells.

Krzysztof Trzciński1, Claudette M Thompson, Amit Srivastava, Alan Basset, Richard Malley, Marc Lipsitch.   

Abstract

CD4(+) T-cell-dependent acquired immunity confers antibody-independent protection against pneumococcal colonization. Since this mechanism is poorly understood for extracellular bacteria, we assessed the antigen specificity of the induction and recall of this immune response by using BALB/c DO11.10Rag(-/-) mice, which lack mature B and T cells except for CD4(+) T cells specific for the OVA(323-339) peptide derived from ovalbumin. Serotype 6B Streptococcus pneumoniae strain 603S and unencapsulated strain Rx1Delta lytA were modified to express OVA(323-339) as a fusion protein with surface protein A (PspA) (strains 603OVA(1) and Rx1Delta lytAOVA(1)) or with PspA, neuraminidase A, and pneumolysin (Rx1Delta lytAOVA(3)). Whole-cell vaccines (WCV) were made of ethanol-killed cells of Rx1Delta lytA plus cholera toxin (CT) adjuvant, of Rx1Delta lytAOVA(1) + CT (WCV-OVA(1)), and of Rx1Delta lytAOVA(3) + CT (WCV-OVA(3)). Mice intranasally immunized with WCV-OVA(1), but not with WCV or CT alone, were protected against intranasal challenge with 603OVA(1). There was no protection against strain 603S in mice immunized with WCV-OVA(1). These results indicate antigen specificity of both immune induction and the recall response. Effector action was not restricted to antigen-bearing bacteria since colonization by 603S was reduced in animals immunized with vaccines made of OVA-expressing strains when ovalbumin or killed Rx1Delta lytAOVA(3) antigen was administered around the time of challenge. CD4(+) T-cell-mediated protection against pneumococcal colonization can be induced in an antigen-specific fashion and requires specific antigen for effective bacterial clearance, but this activity may extend beyond antigen-expressing bacteria. These results are consistent with the recruitment and/or activation of phagocytic or other nonspecific effectors by antigen-specific CD4(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18391006      PMCID: PMC2423086          DOI: 10.1128/IAI.00141-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection.

Authors:  Aras Kadioglu; William Coward; M Joseph Colston; Colin R A Hewitt; Peter W Andrew
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

2.  Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci.

Authors:  R Malley; M Lipsitch; A Stack; R Saladino; G Fleisher; S Pelton; C Thompson; D Briles; P Anderson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  The hemolytic and complement-activating properties of pneumolysin do not contribute individually to virulence in a pneumococcal bacteremia model.

Authors:  K A Benton; J C Paton; D E Briles
Journal:  Microb Pathog       Date:  1997-10       Impact factor: 3.738

4.  Complete genome sequence of a virulent isolate of Streptococcus pneumoniae.

Authors:  H Tettelin; K E Nelson; I T Paulsen; J A Eisen; T D Read; S Peterson; J Heidelberg; R T DeBoy; D H Haft; R J Dodson; A S Durkin; M Gwinn; J F Kolonay; W C Nelson; J D Peterson; L A Umayam; O White; S L Salzberg; M R Lewis; D Radune; E Holtzapple; H Khouri; A M Wolf; T R Utterback; C L Hansen; L A McDonald; T V Feldblyum; S Angiuoli; T Dickinson; E K Hickey; I E Holt; B J Loftus; F Yang; H O Smith; J C Venter; B A Dougherty; D A Morrison; S K Hollingshead; C M Fraser
Journal:  Science       Date:  2001-07-20       Impact factor: 47.728

5.  Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse model.

Authors:  Krzysztof Trzcinski; Claudette Thompson; Richard Malley; Marc Lipsitch
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Destruction of low efficiency markers is a slow process occurring at a heteroduplex stage of transformation.

Authors:  N B Shoemaker; W R Guild
Journal:  Mol Gen Genet       Date:  1974

7.  Low CD4 T cell immunity to pneumolysin is associated with nasopharyngeal carriage of pneumococci in children.

Authors:  Qibo Zhang; Linda Bagrade; Jolanta Bernatoniene; Ed Clarke; James C Paton; Tim J Mitchell; Desmond A Nunez; Adam Finn
Journal:  J Infect Dis       Date:  2007-03-06       Impact factor: 5.226

8.  An rpsL cassette, janus, for gene replacement through negative selection in Streptococcus pneumoniae.

Authors:  C K Sung; H Li; J P Claverys; D A Morrison
Journal:  Appl Environ Microbiol       Date:  2001-11       Impact factor: 4.792

9.  Comparative transcriptional profiling of the lung reveals shared and distinct features of Streptococcus pneumoniae and influenza A virus infection.

Authors:  Simone Rosseau; Andreas Hocke; Hans Mollenkopf; Bernd Schmeck; Norbert Suttorp; Stefan H E Kaufmann; Jens Zerrahn
Journal:  Immunology       Date:  2006-12-08       Impact factor: 7.397

10.  Serum immunoglobulin G response to candidate vaccine antigens during experimental human pneumococcal colonization.

Authors:  Tera L McCool; Thomas R Cate; Elaine I Tuomanen; Peter Adrian; Tim J Mitchell; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

View more
  44 in total

1.  Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.

Authors:  Míriam A da Silva; Thiago R Converso; Viviane M Gonçalves; Luciana C C Leite; Martha M Tanizaki; Giovana C Barazzone
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

2.  A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.

Authors:  Rolando Pajon; Carolyn M Buckwalter; Kay O Johswich; Scott D Gray-Owen; Dan M Granoff
Journal:  Vaccine       Date:  2015-02-04       Impact factor: 3.641

3.  Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine.

Authors:  Shifeng Wang; Yuhua Li; Huoying Shi; Giorgio Scarpellini; Ascencion Torres-Escobar; Kenneth L Roland; Roy Curtiss
Journal:  Infect Immun       Date:  2010-05-17       Impact factor: 3.441

4.  Current advances and challenges in the development of Acinetobacter vaccines.

Authors:  Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  T(H)17-Mediated Protection against Pneumococcal Carriage by a Whole-Cell Vaccine Is Dependent on Toll-Like Receptor 2 and Surface Lipoproteins.

Authors:  K Moffitt; A Howard; S Martin; E Cheung; M Herd; A Basset; R Malley
Journal:  Clin Vaccine Immunol       Date:  2015-06-03

6.  Protection against Streptococcus pneumoniae Invasive Pathogenesis by a Protein-Based Vaccine Is Achieved by Suppression of Nasopharyngeal Bacterial Density during Influenza A Virus Coinfection.

Authors:  M Nadeem Khan; Qingfu Xu; Michael E Pichichero
Journal:  Infect Immun       Date:  2017-01-26       Impact factor: 3.441

7.  Toll-like receptor 2-dependent protection against pneumococcal carriage by immunization with lipidated pneumococcal proteins.

Authors:  Kristin Moffitt; Mojca Skoberne; Angela Howard; L Cristina Gavrilescu; Todd Gierahn; Scott Munzer; Bharat Dixit; Paul Giannasca; Jessica Baker Flechtner; Richard Malley
Journal:  Infect Immun       Date:  2014-03-10       Impact factor: 3.441

8.  Broadly protective protein-based pneumococcal vaccine composed of pneumolysin toxoid-CbpA peptide recombinant fusion protein.

Authors:  Beth Mann; Justin Thornton; Richard Heath; Kristin R Wade; Rodney K Tweten; Geli Gao; Karim El Kasmi; John B Jordan; Diana M Mitrea; Richard Kriwacki; Jeff Maisonneuve; Mark Alderson; Elaine I Tuomanen
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

9.  Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice.

Authors:  D M Ferreira; M Darrieux; D A Silva; L C C Leite; J M C Ferreira; P L Ho; E N Miyaji; M L S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2009-03-11

10.  Streptococcus pneumoniae nasopharyngeal colonization induces type I interferons and interferon-induced gene expression.

Authors:  Elizabeth A Joyce; Stephen J Popper; Stanley Falkow
Journal:  BMC Genomics       Date:  2009-08-27       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.